Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Outcome of bridging therapy in chimeric antigen receptor T cell treatment for Relapsed/Refractory B-cell non-Hodgkin lymphoma: A retrospective study.

View Full Paper
Ask AI
Bookmark
Share

Authors

YHYanjie HeShanghai Jiao Tong UniversityXZXuan ZhouHebei University of TechnologyYLYuhua LiCell Technology (China)

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows limited bridging therapy efficacy in enhancing progression-free survival for B-cell lymphoma patients undergoing CAR-T treatment, indicating careful patient selection is必要

Key Points

  • Assess the impact of bridging therapy on the outcomes of patients with relapsed/refractory B-cell lymphoma receiving CAR-T cell therapy.
  • Retrospective analysis of 88 patients intended for CAR-T therapy between June 2017 and September 2024
  • Comparison between patients who received bridging therapy and those who did not
  • Evaluation of survival rates and safety outcomes, including cytokine release syndrome and hematological toxicity.
  • Bridging therapy group had a median progression-free survival of 104.5 days compared to 505.0 days in the non-bridging group
  • Higher levels of cytokine release syndrome and hematological toxicity in the bridging group
  • Complete response and objective response rates were lower in the bridging group compared to non-bridging group.

Cite This Study

He et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e307https://doi.org/10.1182/blood-2025-8045
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Impact of bridging therapy on efficacy of CD19 CAR T cell therapy in diffuse-large B cell lymphoma: Histology and the choice of drug matter2025
  2. 2Multinational retrospective analysis of bridging therapy prior to chimeric antigen receptor t cells for relapsed/refractory acute lymphoblastic leukemia in children and young adults2025
  3. 3Bridging Therapy's effects on clinical outcomes after commercial BCMA CAR T-cell therapy used in the standard of care treatment of relapsed and refractory multiple myeloma2025
  4. 4Efficacy and safety of bridging versus non-bridging chimeric antigen receptor t-cell therapy in relapsed/refractory diffuse large b-cell lymphoma : A systematic review and meta-analysis2025
  5. 5Current evidence and strategies for bridging therapy in CD19-directed chimeric antigen receptor T-cell therapy for relapsed/refractory large B-cell lymphomas2026